Erratum: CXCL12-mediated monocyte transmigration into brain perivascular space leads to neuroinflammation and memory deficit in neuropathic pain: Erratum

Abstract

[This corrects the article DOI: 10.7150/thno.44364.].

Figure 7

Blocking the CXCL12-CXCR4 pathway reverses SNI-induced cognitive impairment, PVMs increase, and gliosis in the hippocampus. (A) Experimental protocol showing that anti-CXCL12 neutralizing antibody (20 ng/200 μl, i.v.) or CXCR4 antagonist AMD3100 (200 μg/ml, 1 mg/kg, i.p.) or vehicle (Vehi) was applied 30 min before and daily after sham (Sh) or SNI for 9 successive days. On day 9 after the injection, memory function was analyzed with NORT, and mice were perfused for IF and FC. (B) Anti-CXCL12 neutralizing antibody or AMD3100 injection prevented SNI-induced decline in the recognition index but had no effect in sham mice (n =5-12 mice/group). (C-F) Number of PVMs (CD68^high) and the IntDen of CD68^high, PECAM-1, CD11b, and GFAP in the hippocampus in indicated groups. Scale bar = 100 μm. n = 3 mice/group, 3-4 slices/mice. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle sham group, ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. vehicle SNI group, one-way ANOVA with Bonferroni's posthoc test.